Vanda Pharmaceuticals Inc (VNDA) Stock
Fundamentals
Recent news

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
VNDA

Vanda Pharmaceuticals Q2 Earnings Call Highlights
Vanda Pharmaceuticals Q2 Earnings Call Highlights
VNDA

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
VNDA

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
VNDA
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.19 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
VNDA

Vanda Pharmaceuticals Q2 Earnings Call Highlights
Vanda Pharmaceuticals Q2 Earnings Call Highlights
VNDA

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
VNDA

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
VNDA

Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know
Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know
VNDA

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug
VNDA

Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
VNDA

Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections
VNDA

VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains?
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains?
VNDA

VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug
VNDA
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Mihael H. Polymeropoulos M.D. | Founder, President, CEO & Chairman of The Board | 1960 |
| Mr. Kevin Patrick Moran | Senior VP, CFO & Treasurer | 1984 |
| Mr. Joakim Wijkstrom | Senior VP & Chief Marketing Officer | 1966 |
| Mr. Gunther Birznieks | Senior Vice President of Business Development | 1969 |
| Mr. Daniel Patrick McGuire | Senior VP, General Counsel & Secretary | — |
| Mr. Scott L. Howell | Chief People Officer | 1975 |
| Mr. Christos Polymeropoulos M.D. | Senior Vice President & Medical Director | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
3 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.9 | -3.7 | -16.0 | -1.6 | ||||||||
| 2022 | -8.4 | -25.3 | -0.4 | -16.1 | -3.8 | +11.8 | -3.7 | +0.4 | -8.6 | +3.5 | +2.5 | -32.6 |
| 2023 | +3.5 | -16.0 | +5.3 | -10.2 | -7.5 | +11.7 | -10.1 | -8.0 | -15.5 | +5.0 | -14.9 | +8.2 |
| 2024 | -20.4 | +19.8 | -10.8 | +15.5 | +7.1 | +10.4 | +4.7 | -6.2 | -7.7 | +2.4 | +10.5 | -5.0 |
| 2025 | -8.5 | +10.4 | -2.8 | +0.2 | -2.3 | +9.8 | -9.0 | +12.9 | +5.9 | -14.7 | +19.9 | +75.7 |
| 2026 | -8.6 | +15.1 | -15.4 | +0.4 | -7.9 | -3.9 | -15.7 | +3.3 | -6.8 |



